Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
257(c) 250.8(c) 252(c) 254.6(c) 248.1 Last
38 713 72 729 75 904 64 459 13 690 Volume
+3.01% -2.41% +0.48% +1.03% -2.55% Change
More quotes
Estimated financial data (e)
Sales 2021 448 M 507 M 374 M
Net income 2021 -366 M -414 M -305 M
Net cash position 2021 1 617 M 1 832 M 1 349 M
P/E ratio 2021 -38,6x
Yield 2021 -
Sales 2022 131 M 148 M 109 M
Net income 2022 -910 M -1 031 M -759 M
Net cash position 2022 1 046 M 1 185 M 873 M
P/E ratio 2022 -17,6x
Yield 2022 -
Capitalization 13 155 M 14 916 M 10 968 M
EV / Sales 2021 25,8x
EV / Sales 2022 92,6x
Nbr of Employees 336
Free-Float 99,1%
More Financials
Company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme... 
More about the company
Ratings of argenx SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ARGENX SE
01/20Health Care Stocks Advance Premarket Thursday
MT
01/20ARGENX : announces VYVGART™ approval in Japan for the treatment of generalized myast..
PU
01/20Argenx Secures Japan's Approval for Generalized Myasthenia Gravis Drug Vyvgart
MT
01/20Argenx Neuromuscular Disease Drug Wins Japanese Nod
MT
01/20argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myas..
BU
01/20argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia ..
CI
01/18Morgan Stanley Adjusts argenx's Price Target to $339 from $351, Keeps Equalweight Ratin..
MT
01/07Wedbush Adjusts argenx SE Price Target to $382 From $362, Maintains Outperform Rating
MT
01/07European ADRs Move Higher in Friday Trading
MT
01/07ARGENX : Highlights Strategic Priorities for 2022 - Form 6-K
PU
01/07argenx Highlights Strategic Priorities for 2022
BU
01/04ARGENX : argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
PU
01/03Argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ARGENX SE : Crossing thresholds
CO
2021ARGENX : Announces U.S. Food and Drug Administration (FDA) Approval of VYVGARTÔ (efgartigi..
PU
More news
News in other languages on ARGENX SE
01/20Les actions du secteur de la santé progressent jeudi avant le marché
01/20Brussel blijft in het rood
01/20Brussel koerst weer lager
01/20Le médicament d'Argenx contre les maladies neuromusculaires reçoit l'aval du Japon
01/20Argen-x krijgt Japanse goedkeuring voor behandeling myasthenia gravis
More news
Analyst Recommendations on ARGENX SE
More recommendations
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 254,60 €
Average target price 334,64 €
Spread / Average Target 31,4%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE-19.25%14 916
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805